Cargando…
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series
Tumor lysis syndrome (TLS) occurs in malignancies with high proliferative potential and tumor burden, such as lymphomas and leukemias. TLS syndrome is an oncologic emergency, requiring prompt intervention. The metabolic derangements cause acute kidney failure and may lead to cardiac arrhythmias, sei...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379632/ https://www.ncbi.nlm.nih.gov/pubmed/25838646 http://dx.doi.org/10.4103/0971-4065.139092 |
_version_ | 1782364220600352768 |
---|---|
author | Latha, S. M. Krishnaprasadh, D. Murugapriya, P. Scott, J. X. |
author_facet | Latha, S. M. Krishnaprasadh, D. Murugapriya, P. Scott, J. X. |
author_sort | Latha, S. M. |
collection | PubMed |
description | Tumor lysis syndrome (TLS) occurs in malignancies with high proliferative potential and tumor burden, such as lymphomas and leukemias. TLS syndrome is an oncologic emergency, requiring prompt intervention. The metabolic derangements cause acute kidney failure and may lead to cardiac arrhythmias, seizures, and death. With the advent of rasburicase, a recombinant urate oxidase, there has been a decline in the TLS-mediated renal failure and the need for dialysis. The recommended regimen and doses pose a heavy financial burden for patients in developing countries like India. With data and studies proving a similar efficacy for the reduced dose and lesser number of rasburicase, we report here a case series of seven children with acute leukemias, whose TLS was managed by a single dose of rasburicase. A retrospective analysis of case records of seven children with acute lymphoblastic leukemia and TLS, admitted to our Pediatric Oncology Unit of our Hospital between the period 2011 and 2013, was done. All our patients responded to a single dose, indicating that in appropriately monitored patients, single dose followed by as-needed dosing can be cost-saving. |
format | Online Article Text |
id | pubmed-4379632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43796322015-04-02 Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series Latha, S. M. Krishnaprasadh, D. Murugapriya, P. Scott, J. X. Indian J Nephrol Original Article Tumor lysis syndrome (TLS) occurs in malignancies with high proliferative potential and tumor burden, such as lymphomas and leukemias. TLS syndrome is an oncologic emergency, requiring prompt intervention. The metabolic derangements cause acute kidney failure and may lead to cardiac arrhythmias, seizures, and death. With the advent of rasburicase, a recombinant urate oxidase, there has been a decline in the TLS-mediated renal failure and the need for dialysis. The recommended regimen and doses pose a heavy financial burden for patients in developing countries like India. With data and studies proving a similar efficacy for the reduced dose and lesser number of rasburicase, we report here a case series of seven children with acute leukemias, whose TLS was managed by a single dose of rasburicase. A retrospective analysis of case records of seven children with acute lymphoblastic leukemia and TLS, admitted to our Pediatric Oncology Unit of our Hospital between the period 2011 and 2013, was done. All our patients responded to a single dose, indicating that in appropriately monitored patients, single dose followed by as-needed dosing can be cost-saving. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4379632/ /pubmed/25838646 http://dx.doi.org/10.4103/0971-4065.139092 Text en Copyright: © Indian Journal of Nephrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Latha, S. M. Krishnaprasadh, D. Murugapriya, P. Scott, J. X. Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series |
title | Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series |
title_full | Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series |
title_fullStr | Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series |
title_full_unstemmed | Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series |
title_short | Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series |
title_sort | single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: a case series |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379632/ https://www.ncbi.nlm.nih.gov/pubmed/25838646 http://dx.doi.org/10.4103/0971-4065.139092 |
work_keys_str_mv | AT lathasm singledoserasburicaseinthemanagementoftumorlysissyndromeinchildhoodacutelymphoblasticleukemiaacaseseries AT krishnaprasadhd singledoserasburicaseinthemanagementoftumorlysissyndromeinchildhoodacutelymphoblasticleukemiaacaseseries AT murugapriyap singledoserasburicaseinthemanagementoftumorlysissyndromeinchildhoodacutelymphoblasticleukemiaacaseseries AT scottjx singledoserasburicaseinthemanagementoftumorlysissyndromeinchildhoodacutelymphoblasticleukemiaacaseseries |